Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
The ONCT news page on Stock Titan aggregates press releases and other coverage related to Oncternal Therapeutics, Inc., a company that has been described in its own communications as a clinical-stage biopharmaceutical developer of oncology therapies. These news items trace both the evolution of its investigational pipeline and its later strategic decisions, giving investors and researchers a consolidated view of the company’s trajectory.
Earlier news focuses on clinical and operational updates for programs such as ONCT-534, an investigational dual-action androgen receptor inhibitor evaluated in metastatic castration-resistant prostate cancer, and ONCT-808, an autologous CAR T cell therapy targeting ROR1 in relapsed or refractory aggressive B-cell lymphoma. Releases detail dose-escalation cohorts, safety and tolerability observations, interim efficacy signals based on measures like prostate-specific antigen levels, and protocol amendments in ongoing Phase 1/2 studies.
Other articles describe the broader pipeline, including zilovertamab, a monoclonal antibody targeting ROR1 studied in combination with ibrutinib and in investigator-initiated trials, and ONCT-216, a small-molecule inhibitor of ETS family oncoproteins with regulatory designations for Ewing sarcoma. These pieces provide context on the scientific rationale and clinical settings in which the agents have been tested.
More recent news documents a shift in corporate direction. A September 2024 press release announces the termination of clinical studies for ONCT-534 and ONCT-808, the discontinuation of product development activities and the exploration of strategic alternatives. A July 2025 release reports the sale of the zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. and states that a new executive will oversee the winddown of Oncternal’s operations. Together, these items form a historical record of how the ONCT story moved from active clinical development toward asset sales and an operational wind-down.
Users interested in ONCT news can review this stream to understand the company’s investigational programs, clinical milestones, strategic reviews and the subsequent wind-down steps described by Oncternal in its own announcements.
Oncternal Therapeutics announced an inducement award to new Clinical Trial Manager Mohab Hassanin on November 1, 2021. The award includes an option to purchase 34,100 shares of common stock, vesting over four years. This grant aligns with the company’s 2021 Employment Inducement Incentive Award Plan and complies with Nasdaq rules. The company focuses on innovative oncology therapies addressing critical needs, including cirmtuzumab in trials for mantle cell lymphoma and breast cancer, and TK216 for Ewing sarcoma.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its third quarter 2021 financial results after U.S. markets close on November 4, 2021. A management webcast will occur at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a business update. The company focuses on developing novel oncology therapies, including cirmtuzumab, targeting ROR1, and TK216 for Ewing sarcoma. Oncternal's innovative clinical pipeline addresses significant unmet needs in cancer treatment.
Oncternal Therapeutics (Nasdaq: ONCT) announced preclinical data for ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, set to be presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. ONCT-534 aims to address significant unmet needs in treating Castration-Resistant Prostate Cancer (CRPC), particularly against AR splice variant AR-V7. The data, demonstrating anti-tumor activity, may pave the way for ONCT-534 as a next-generation treatment for prostate cancers resistant to current therapies.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced on October 1, 2021, that it has granted equity inducement awards to new employees, including Vice President Emily Samec. The awards include options to purchase a total of 364,900 shares of common stock, with a 10-year term and an exercise price reflecting the closing stock price on the grant date. The options vest over four years, aligning with Nasdaq regulations. Oncternal focuses on innovative oncology therapies, with ongoing clinical trials for candidates like cirmtuzumab and TK216 aimed at addressing significant cancer needs.
Oncternal Therapeutics (Nasdaq: ONCT) and Celularity (Nasdaq: CELU) announced a research collaboration on Sept. 20, 2021, to explore placental-derived cellular therapies targeting ROR1. The partnership will investigate the use of Oncternal's anti-ROR1 monoclonal antibody, cirmtuzumab, alongside Celularity's natural killer cells. Cirmtuzumab has shown potential in reducing tumor cell proliferation in hematological malignancies. Both companies aim to enhance therapeutic strategies for various cancers, leveraging placental-derived cells to overcome current treatment limitations.
Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, will participate in three virtual conferences in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 11:35 am ET, and the Cantor Global Healthcare Conference on September 29 at 11:20 am ET. Webcasts and replays will be available on their investor page.
Oncternal Therapeutics announced the appointment of Steven Hamburger, Ph.D., as Senior Vice President of Regulatory Affairs and Quality Assurance. Dr. Hamburger has over 35 years of experience in drug development, with a focus on oncology and rare diseases. His role is expected to enhance Oncternal's ongoing discussions with the FDA regarding a potential registration study for cirmtuzumab, aimed at treating mantle cell lymphoma. Additionally, inducement awards for stock options were granted to Dr. Hamburger and another new employee to incentivize their joining.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) reported encouraging interim clinical data for cirmtuzumab and TK216 at ASCO 2021. The combination of cirmtuzumab with ibrutinib showed an objective response rate of 83% in heavily pre-treated mantle cell lymphoma (MCL) patients. New treatment cohorts have been added for both MCL and Ewing sarcoma. Financially, Oncternal reported a net loss of $7.7 million for Q2 2021 with $103.7 million in cash, sufficient to support operations into 2023. The management team has been strengthened with new appointments.
Oncternal Therapeutics (Nasdaq: ONCT) announced on August 2, 2021, the granting of inducement awards to two new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The awards include options for a total of 216,400 shares of common stock, with a 10-year term and an exercise price matching the stock's closing price on the grant date. Vesting occurs over four years, beginning with 25% after one year. The compensation committee, composed of independent directors, approved these awards in compliance with Nasdaq regulations.
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT) announced participation in the BTIG Virtual Biotechnology Conference scheduled for August 9-10, 2021. James Breitmeyer, President and CEO, will present a corporate overview on August 9 at 12:00pm (ET) and will be available for one-on-one meetings. Oncternal is focused on developing novel oncology therapies, including cirmtuzumab and TK216, addressing critical cancer treatment needs.